Voyager Therapeutics names Robin Swartz President ahead of CEO handover
Voyager Therapeutics has appointed Robin Swartz as President with immediate effect, setting in motion a planned leadership transition at the Lexington, Massachusetts-based neurological gene therapy company. Swartz, who has served as both Chief Business Officer and Chief Operating Officer, is expected to assume the role of Chief Executive Officer in the first quarter of 2027, succeeding Alfred W. Sandrock Jr., who has led the company for five years.
The timing of the handover is deliberately anchored to a clinical milestone. Sandrock has said he intends to remain CEO until Voyager receives initial acute safety data from its Phase 1 trial of VY1706, an investigational tau-silencing gene therapy being evaluated in adults with early Alzheimer's disease. That data readout is anticipated in early 2027, subject to enrolment. Following the transition, Sandrock will remain on Voyager's Board of Directors.
A pipeline-tied transition
Linking a leadership change to a data event is relatively uncommon but signals the Board's view that VY1706 represents the company's most consequential near-term inflection point. VY1706 is designed to silence tau, a protein whose abnormal accumulation is associated with neurodegeneration in Alzheimer's disease and a number of related conditions. The gene therapy is delivered using Voyager's proprietary TRACER AAV capsid platform, which the company has developed to enable high brain penetration following intravenous dosing, addressing one of the longstanding barriers to CNS gene therapy.
Michael Higgins, Chairman of the Board, said Swartz was "unanimously selected" by the Board as the most qualified candidate, citing her "strategic vision, commitment to patients, and proven ability to consistently deliver results."
Swartz joined Voyager in 2021 after 26 years at Genzyme Corporation and Sanofi Genzyme, where she held senior roles spanning commercial, development, business operations, and finance. At Voyager she has had broad remit, overseeing clinical development, finance, legal, human resources, portfolio strategy, and patient engagement alongside her business and operational responsibilities. That breadth of experience is likely to matter as the company advances from a platform-building phase toward the commercial realities of late-stage development.
Market and competitive context
The Alzheimer's gene therapy field is nascent but attracting sustained interest. While antibody-based approaches targeting amyloid have dominated the Alzheimer's treatment landscape in recent years, tau-directed strategies represent an alternative disease-modifying axis, and several programmes from academic groups and biotechs are pursuing tau suppression through different modalities, including antisense oligonucleotides and small molecules. Voyager's AAV-based approach is differentiated by its intravenous delivery route, which it says its TRACER capsids make feasible for CNS targets.
Voyager's broader pipeline spans Friedreich's ataxia, Parkinson's disease, and amyotrophic lateral sclerosis, and several programmes are partnered with Alexion, AstraZeneca Rare Disease, Novartis, and Neurocrine Biosciences. Those partnerships provide non-dilutive funding and validate the platform's external credibility, though they also create dependency on partner decisions that sit outside Voyager's direct control.
For investors, the key watch points remain enrolment pace in the VY1706 trial and the nature of the acute safety data expected to trigger the CEO transition. A clean safety profile would meaningfully de-risk the programme and likely mark Swartz's first major public milestone as incoming chief executive.